UC Irvine
UC Irvine Previously Published Works

Title

Gestational organophosphate ester exposure and preschool attention-deficit/hyperactivity disorder in the Norwegian Mother, Father, and Child cohort study.

Permalink

https://escholarship.org/uc/item/9hh2920f

Authors

Hall, Amber
Ramos, Amanda
Drover, Samantha
et al.

Publication Date

2023-03-01

DOI

10.1016/j.ijheh.2022.114078

Peer reviewed

Gestational Organophosphate Ester Exposure and Preschool Attention-Deficit/Hyperactivity Disorder in the Norwegian Mother, Father, and Child Cohort Study

Amber M. Hall[a,1], **Amanda M. Ramos**[a], **Samantha SM Drover**[b], **Giehae Choi**[c], **Alexander P. Keil**[a], **David B. Richardson**[a], **Chantel L. Martin**[a], **Andrew F. Olshan**[a], **Gro D. Villanger**[d], **Ted Reichborn-Kjennerud**[e,f], **Pål Zeiner**[g], **Kristin R. Øvergaard**[e,g], **Amrit K. Sakhi**[h], **Cathrine Thomsen**[h], **Heidi Aase**[d], **Stephanie M. Engel**[a]

[a]Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA

[b]Department of Public Health Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada

[c]Department of Environmental Health and Engineering, Johns Hopkins University, Baltimore, MD, USA

[d]Department of Child Health and Development, Division of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway

[e]Institute of Clinical Medicine, University of Oslo, Oslo, Norway

[f]Department of Mental Disorders, Division of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway

[g]Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway

[1]Corresponding author present address: Department of Epidemiology, Brown School of Public Health, 121 S. Main St. GS-121-(2), Providence, RI 02912. amber_hall@brown.edu.

Ethics: The MoBa study was conducted with a license from the Norwegian Data Protection Agency in accordance with guidelines from the Declaration of Helsinki. The MoBa study is currently regulated by the Norwegian Health Registry Act. The Preschool ADHD study was approved by the Regional Committee for Medical and Health Research Ethics South East Norway (ref. nu. 2011/179). Written informed consent was required and obtained for all participants in MoBa. Similarly, additional approval and written informed consent of participants for the clinical evaluation was required and obtained by the Regional Committee for Medical Research Ethics (ref. nu. 2012/985). Data analyses were performed with approval of the UNC Office of Human Research Ethics (ref. nu. 20–2462).

Declarations or Conflicts of Interest: None.

Data Statement: Data from MoBa and the Medical Birth Registry of Norway used in this study are managed by the national health register holders in Norway (Norwegian Institute of Public Health; NIPH) and can be made available to researchers, provided approval from the Regional Committees for Medical and Health Research Ethics (REC), compliance with the European Union General Data Protection Regulation (GDPR) and approval from the data owners. The consent given by the participants does not open for storage of data on an individual level in repositories or journals. Researchers who want access to data sets for replication should apply through helsedata.no. Access to data sets requires approval from REC in Norway and an agreement with MoBa Analytic code used for the present analysis may be obtained from the corresponding author.

[h]Department of Food Safety, Division of Climate and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.

Abstract

Background: Attention-deficit/hyperactivity-disorder (ADHD) is a leading neurodevelopmental disorder in children worldwide; however, few modifiable risk factors have been identified. Organophosphate esters (OPEs) are ubiquitous chemical compounds that are increasingly prevalent as a replacement for other regulated chemicals. Current research has linked OPEs to neurodevelopmental deficits. The purpose of this study was to assess gestational OPE exposure on clinically-assessed ADHD in children at age 3 years.

Methods: In this nested case-control study within the Norwegian Mother, Father, and Child Cohort study, we evaluated the impact of OPE exposure at 17 weeks' gestation on preschool-age ADHD. Between 2007 and 2011, 260 ADHD cases were identified using the Preschool Age Psychiatric Assessment and compared to a birth-year-stratified control group of 549 children. We categorized bis(2-butoxyethyl) phosphate (BBOEP) and bis(1,3-dichloro-2-propyl) phosphate (BDCIPP) as values <limit of detection (LOD) (BBOEP N= 386, BDCIPP N= 632), ≥ LOD but <limit of quantification (LOQ) (BBOEP N= 413; BDCIPP N=75), or above LOQ (BBOEP N= 70; BDCIPP N=102). Diphenyl phosphate (DPhP) and di-n-butyl phosphate (DnBP) were categorized as quartiles and also modeled with a log10 linear term. We estimated multivariable adjusted odds ratios (ORs) using logistic regression and examined modification by sex using an augmented product term approach.

Results: Mothers in the 3rd DnBP quartile had 1.71 times the odds of having a child with ADHD compared to the 1st quartile (95%CI: 1.13, 2.58); a similar trend was observed for log10 DnBP and ADHD. Mothers with BDCIPP ≥ LOD but <LOQ had 1.39 times the odds of having a child with ADHD compared to those with BDCIPP <LOD (95%CI: 0.83, 2.31). Girls had lower odds of ADHD with increasing BBOEP exposure (log10 OR: 0.55 (95%CI: 0.37, 0.93), however boys had a weakly increased odds (log10 OR: 1.25 (95%CI: 0.74, 2.11) p-interaction=0.01].

Conclusions: We found modest increased odds of preschool ADHD with higher DnBP and BDCIPP exposure.

Keywords

MoBa; organophosphate ester; preschool; ADHD; flame retardant; neurodevelopment

Introduction

Organophosphate esters (OPEs) are ubiquitous chemicals, generally used as flame retardants and/or plasticizers[1], found in a multitude of everyday items such as household furniture[1], electronics[1], baby products[2], personal care products[3,4], and nail polish[3–5]. OPE usage has substantially increased over time as a replacement for other regulated chemicals such as polybrominated diphenyl esters (PBDEs) and polychlorinated biphenyls (PCBs), that have been previously phased out due to their potential toxicity, ability to bioaccumulate, and environmental persistence.[1,6,7] Although OPEs do not bioaccumulate, they can leach into

the surrounding environment where they are capable of entering the human body through inhalation, dermal absorption, and/or ingestion of contaminated food or water.[1]

There has been growing concern regarding OPEs due to their ubiquitous distribution and potential for adverse human health effects. Recent epidemiological studies have found associations between OPEs and adverse neurodevelopmental-[8–12], thyroid-based-[13,14], reproductive-[15–17], respiratory-[18–20], and dermal-[19] endpoints; however, some studies have found no association[21,22]. OPE exposure during the gestational period is of significant interest because OPEs can cross the placental barrier[23,24] and may accumulate in the placenta[23] and/or amniotic fluid[25].

Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder commonly diagnosed in childhood, but symptoms of ADHD may emerge as early as the preschool period.[26] Estimates of the persistence of ADHD from preschool through childhood vary[27–29], however early identification and treatment of ADHD may have benefits, due to the substantial adverse individual[30–35] and economic[36–41] burdens associated with this disorder.

Several studies suggest gestational OPE exposure is associated with risk of ADHD or ADHD-like behaviors.[9,11,12] The only study to date to evaluate this association with ADHD as a clinical diagnosis was conducted by Choi (2021) et al. using a nested case-control study, also within the Norwegian Mother, Father, and Child cohort (MoBa).[12] Choi et al. examined gestational OPE concentrations in relation to a diagnostic code registration of ADHD among children in the Norwegian National Patient Registry (NPR).[12] Choi et al. reported that higher gestational concentrations of diphenyl phosphate (DPhP) and bis(1,3-dichloro-2-propyl) phosphate (BDCIPP) were associated with elevated risk of childhood ADHD registration. While preschool ADHD is correlated with childhood ADHD, it is not perfectly predictive.[27–29] Furthermore, diagnostic registrations of ADHD may be affected by variability in clinical practice, over-representation of more severe and disruptive cases, and an under-representation of girls. To date, all the studies we identified that evaluated associations of individual OPEs on ADHD, assessed and found evidence of an association between BDCIPP and ADHD or ADHD-like symptoms. Similarly, the majority of such studies have found evidence of associations with DPhP. Fewer consistent patterns exist for other OPEs, and, overall, there is a lack of agreement as to the existence of sex-specific effects[9,11,12], with Choi et al. observing larger adverse associations among girls[12] and three other studies observing no appreciable sex-related effect measure modification (EMM)[9,11]. As such, the purpose of this study is to examine whether gestational OPE exposure may impact early manifestation of ADHD, specifically in relation to preschoolers.

A potential causal link between OPEs and ADHD could result in public health interventions with a meaningful impact through regulatory changes. As such, this study has the potential to identify or dismiss a modifiable cause of one of the leading neurodevelopmental disorders in preschoolers worldwide. To address this important question, we leverage a nested Preschool ADHD Substudy of MoBa, in which a high-quality standardized on-site clinical evaluation of all children was conducted, to determine the potential impact of OPEs

on preschool ADHD. To evaluate potential sex differences in associations, we examined sex-related modification of the OPE-ADHD association in preschoolers.

Material and Methods

Study population

MoBa is an ongoing, prospective population-based cohort study of pregnant Norwegian-speaking women enrolled between 1999 and 2008.[42,43] Women consented to participation at their first ultrasound appointment (~17 weeks' gestation) and, upon enrollment, blood and urine samples were collected. Questionnaires were completed by mothers at 17-, 22-, and 30-weeks' gestation as well as longitudinally after birth.[43] Of the original 227,702 pregnancies invited, 40.7% (N = 112,908 pregnancies; 95,200 women) agreed to participate, of which ~107,000 children are still actively enrolled.[43,44]

This ADHD Substudy of MoBa consisted of children born between April 2004 and January 2008 that were the result of a singleton pregnancy, resided within close proximity to Oslo, did not meet criteria for the Autism Birth Cohort study[45], and with completed 36-month postnatal questionnaire.[46] Included in the 36-month questionnaire were 11 questions aimed at identifying children displaying ADHD-like behaviors.[47,48] These questions included 5 from the Diagnostic and Statistical Manual of Mental Disorders, Version 4, Text Revision[49] (DSM-IV-TR; easily distracted, difficulty waiting his/her turn, difficulty sustaining attention, talks excessively, and does not seem to listen) and 6 from the Child Behavior Checklist/1.5–5[50] (can't concentrate, can't sit still, can't stand waiting, demands must be met immediately, gets into everything, and quickly shifts activities).[48] From these questions, we developed a quantitative index, referred to as the "sampling screener".[48] Children from the ADHD eligible population that scored in the 90th percentile or higher on this screener were automatically invited to participate in an on-site clinical evaluation (N=2,798) as well as a small random sample of children from the ADHD eligible population (N=654). Of the original 3,452 pregnancies invited, 1,195 (34.6% participation rate) agreed to participate, 870 of which had a maternal urine sample available. This substudy of children that underwent clinical examination is referred to as the MoBa ADHD Substudy. Children that participated in the clinical evaluation were between 3.1 and 3.8 years of age.[51,52] A flow diagram outlining selection into our current study can be viewed in Supplemental Figure 1. The original study design was a case-cohort design, but we excluded cases from the referent sub-cohort in our study. As such, the current study design is a case-control design; control selection is discussed in more detail in the section 'selection of controls'.

Selection of preschool ADHD cases

In contrast to the study by Choi et al. who used primarily childhood ADHD cases as the study outcome (i.e. children ages 6 to 11 years), we utilized children with preschool ADHD defined as children ages 2 to 5 years (all children in this study were 3 years old).[12,53] Preschool ADHD differs from childhood ADHD in relation to symptom occurrence (proportion of hyperactive vs inattentive cases) and symptom severity, with both occurrence and severity declining between preschool and late childhood, particularly in relation to

hyperactivity.[27,29,54–56] As such, preschool ADHD is predictive but not perfectly correlated with childhood ADHD. [27–29]

In our study, preschool ADHD status was determined using the Preschool Age Psychiatric Assessment (PAPA).[57] PAPA is an interviewer-based psychiatric instrument, validated in children 2 to 5 years, and provides information on the magnitude and frequency of neurodevelopmental symptoms set forth in the DSM-IV-TR.[49,57,58] PAPA is not equivalent to a clinical diagnosis as this requires a more in-depth evaluation from multiple sources. In this study, trained graduate psychology students conducted standardized and structured psychiatric interviews using PAPA with a caregiver (generally the mother) under the supervision of a child psychologist or psychiatrist; all parents of children who participated in the 1-day clinical exam were interviewed with PAPA.[59] Preschool ADHD symptoms were counted as present if they persistent for 3-months or more across at least 2 settings.[57] The inter-rater reliability of PAPA for preschool ADHD symptoms in our study was assessed by having a second blinded rater rescore the audiotapes of 79 interviews and found to be high (total preschool ADHD symptoms interclass correlation coefficient: 0.98).[60] At the end of the ADHD section in PAPA, an impairment/impact section was also administered to participants who reported at least one ADHD symptom.[61] This section consisted of six functional domains (family relationships, friends, learning, play/leisure activities, child's quality of life, and family burden).[61] Each functional domain was scored on a 4-point Likert scale (0, 1, 2, or 3 points) for a possible total of 18 points.[61] Impairment was considered present when the child scored 2 or higher overall (sum score).[44]

In this study, a child was classified as meeting clinical criteria for ADHD if they had 6 or more symptoms (from a possible 9 symptoms) on PAPA and was also scored as having an impairment.[44,57] Children who presented with 6 or more preschool ADHD symptoms but no impairment or 3 to 5 preschool ADHD symptoms and an impairment were classified as having subclinical ADHD.[44] For this study, we considered children to have preschool ADHD if they score in the clinical (n = 114) or subclinical (n = 146) range on the PAPA for a total of 260 children hereafter referred to as "preschool ADHD cases".[44,57]

Selection of controls

We selected a birth-year stratified random sample of participants, representative of the ADHD eligible population (i.e., representing the exposure distribution that gave rise to the cases), as a comparison group for the preschool ADHD cases (n=556). This random sample was frequency matched to preschool ADHD cases on birth year and did not undergo clinical evaluation. Because only 7 preschool ADHD cases were also included in the random sample, we treated these children as preschool ADHD cases only, resulting in 549 children in the final control group.

Measurement of organophosphate ester (OPE) metabolites

Details regarding urine collection and analysis have been previously published.[12,62,63] Briefly, urine samples were collected ~17 weeks' gestation at which time they were shipped unrefrigerated overnight to the central biorepository in Oslo, Norway for immediate processing.[12,62,63] Bacterial growth was prevented during shipment through the inclusion

of chlorhexidine.[64] The majority of samples were received within one (66%) or two (10%) days of collection. All samples were processed the day of receipt and less than 1% underwent freeze-thaw cycles.[64] Standard operating procedures were derived for comprehensive quality insurance. A laboratory information management system was used to prevent sample identity errors and track specimens.

In this study, we measured 4 OPE metabolites using ultra performance liquid chromatography (UPLC) coupled with quadrupole-time-of-flight.[65,66] These metabolites were di-n-butyl phosphate (DnBP), DPhP, BDCIPP, and bis(2-butoxyethyl) phosphate (BBOEP), which correspond with the parent compounds tri-n-butyl phosphate (TnBP), triphenyl phosphate (TPhP), tris (1,3-dichloro-2-propyl) phosphate (TDCIPP), and tris (2-butoxethly) phosphate (TBOEP) respectively.

Quality control procedures have been detailed previously.[66,67] Briefly, 2 in-house control samples and 4–6 quality controlled pooled urine samples were included per analytic batch to assess assay precision and batch-batch variability respectively and cases and controls were randomized to batch. To account for urine dilution, we measured specific-gravity using a pocket refractometer (PAL-10S) from Atago.

Statistical analysis

Data analysis was based on version 9 of the quality-assured MoBa data files. We selected potential confounders *a priori* from the OPE-ADHD literature and assessed their relationship via direct acyclic graph (DAG) (Supplemental Figure 2).[68] From this DAG, we determined a minimally-sufficient adjustment set (MSS). The covariates in the MSS included maternal fish intake,[69,70] birth year, child sex, family income, maternal age at delivery, and maternal education. From the Medical Birth Registry of Norway, we obtained maternal age at delivery, child sex (male/female), and birth year. We derived information on maternal education (< 4-year college degree, 4-year college degree, post-graduate degree or higher), marital status (married, single/co-habiting), parity (nulliparous/parous), financial difficulty in the past 6 months (yes/no), and maternal smoking during pregnancy (yes/no) and maternal drinking during pregnancy (yes/no) from the 17-gestational-weeks' questionnaire. We determined maternal fish intake from a semiquantitative food frequency questionnaire administered at 22-gestational-weeks' and calculated servings per day for total fish consumption by summing daily, weekly, and monthly intake.[71] Additionally, we derived a binary indicator of maternal ADHD symptoms via the Adult ADHD Self-Report Scales (ASRS), a validated assessment for adult ADHD symptoms that was completed as part of the 36-month questionnaire.[72] As maternal ADHD may confound the OPE-offspring ADHD relationship due to its high heritability[73–76] and potential to affect OPE exposure levels through an unknown confounding pathway, we considered maternal ADHD for inclusion in our models in addition to covariates in the MSS. To address concerns regarding positivity, we removed variables that had a minimal impact on the final effect estimates and did not improve model fit for parsimony. Covariates in the final models included total fish consumption, maternal education, financial difficulty, maternal age, and child sex.

As BBOEP and BDCIPP both had more than 50% of their values below the limit of detection (LOD), we categorized these 2 OPEs as < LOD, LOD to < limit of quantification

(LOQ), and LOQ because, imputation of these variables in a continuous form could potentially introduce bias.[77] Next, we adjusted OPE concentrations for urine dilution using specific-gravity as described by Hauser (2004) et al.[78] For other OPEs, we imputed exposure values below the LOD and missing covariate data from a log-normal distribution using a multivariate imputation by chained equation (MICE) approach (m=20), with exposure data truncated at the LOD, and conditional on outcome, exposure, and other covariates. From this, we obtained summary estimates via Rubin's rules for imputation.[77,79–81]

We calculated outcome-stratified Spearman correlations between non-imputed and imputed specific-gravity-corrected OPEs to determine correlations between exposure variables. We then determined optimal functional forms of OPEs and covariates from bivariate assessments and multivariable logistic regression models, with an emphasis on minimizing Akaike Information Criterion. Next, we created quartile cutpoints for DPhP and DnBP concentrations based on the birth-year-stratified control group to represent the exposure distribution in the study base. We modeled DPhP and DnBP continuously using a log10 transformation and as quartiles to allow for nonlinear and/or non-monotonic trends. To estimate the association between each OPE and preschool ADHD, we calculated odds ratios (ORs) using logistic regression models, adjusted for covariates.

We assessed child sex as a potential effect measure modifier on the multiplicative scale using an augmented product term approach.[82] We considered EMM to be present if the p-value for the interaction term between child sex and OPE was at or below the *a priori* threshold of 0.10. All analyses were performed using SAS 9.4 (Cary, NC).

Sensitivity analyses

To assess the impact of imputing missing covariate data, we reran models without covariate imputation. To account for the potential influence of correlated OPE metabolites, we reran models co-adjusting for the other three main metabolites (one at a time). To investigate any potential batch-effects, we reran models excluding one batch at a time to determine if the exclusion of any single batch meaningfully impacted any of the final associations.

Results

Fifty-six percent of preschool ADHD cases were boys; however, child sex was equally distributed in our control group (Table 1). Mothers in our study averaged ~30 years of age at delivery. Mothers of children with preschool ADHD were less likely to be college educated (63% vs 74%) and more likely to be nulliparous (60% vs 49%), smoke during pregnancy (24% vs 14%), and report experiencing more financial difficulty (26% vs 14%) compared to mothers of children in the control group (Table 1). No covariate in our study had more than 10% missingness (Table 1).

DPhP and DnBP were usually detected, with greater than 90% of values above the LOD; as noted above, BBOEP and BDCIPP were less frequently detected (Table 2). Geometric means and percentiles for OPE metabolite measures were comparable between preschool ADHD cases and controls. OPE metabolites were minimally correlated, with Spearman

correlations ranging from |0.020| to |0.345| for non-imputed measures (Supplemental Table 1A); imputation had little effect on these correlations (Supplemental Table 1B).

Mothers in the 3rd DnBP quartile had 1.71 times the odds (95%CI: 1.13, 2.58) of having a child with preschool ADHD compared to the 1st quartile; however, across quartiles of DnBP, the trend did not appear monotonic (Figure 1; Supplemental Table 2). Similarly, increased log10 DnBP exposure was also association with higher odds of ADHD [OR: 1.30; 95%CI: 0.86, 1.97); Table 3]. Some quantile- or category- specific ORs were elevated, for example BDCIPP measures LOD but <LOQ had 1.39 times the odds (95%CI: 0.83, 2.31) of having a child with preschool ADHD compared to those with BDCIPP measures <LOD (Figure 1; Supplemental Table 2). However, we did not observe monotonic patterns of association for any OPE. Results from multiply-imputed models were consistent with those from a complete case analysis (Supplemental Table 2). Furthermore, associations were not meaningfully affected by mutual adjustment for any other OPE metabolite (Supplemental Table 3), and no batch-effects were observed (Supplemental Figures 3A-3D).

A product term between BBOEP and child sex was statistically significant, suggesting multiplicative EMM (p-interaction 0.01; Table 3). Specifically, girls had lower conditional odds of preschool ADHD with BBOEP exposure above the LOD, whereas the result for boys suggested associations that were null or in the opposite direction. [Girls: log10 OR: 0.55 (95%CI: 0.37, 0.93); Boys: log10 OR: 1.25 (95%CI: 0.74, 2.11); p=0.01]. No notable EMM was observed for any other OPE.

Discussion

Using a nested case-control subset of MoBa, we examined the relationship between gestational OPE exposure and preschool ADHD. We found some evidence that gestational exposure to DnBP and BDCIPP may be associated with increased odds of ADHD, although associations were modest in magnitude and did not follow a monotonic exposure-response trend. We observed evidence of heterogeneity by child sex for BBOEP and preschool ADHD, with girls having lower odds of preschool ADHD with increased exposure, while boys trending in the opposite direction. However, no other OPE association evidenced modification by child sex.

There is a very limited epidemiological literature on gestational exposure to OPEs and child neurodevelopment; however, substantial concern exists for their potential impact on human neurodevelopment due to their ubiquitous distribution and potential to disrupt neurological process.[83,84] Studies on PC12 human cells have found OPEs may inhibit DNA synthesis[83] and/or total acetylcholinesterase activity[84], disrupt cell proliferation[84], and increase neurodifferentiation into cholinergic and/or dopaminergic phenotypes[83].

Four epidemiological studies have assessed OPE exposure and ADHD or ADHD-like symptoms, all observing associations with some OPE metabolites.[8,9,11,12] The only study to investigate behavioral symptoms in the preschool period was by Doherty (2019) et al.[11] They found higher gestational DPhP and BDCIPP exposure was related to more behavioral and externalizing problems in 3 year-old children in North Carolina, with both

DPhP and BDCIPP associated with more attention problems and BDCIPP related to greater hyperactivity.[11] However, our results were not entirely consistent with their study. We found little evidence of association with DPhP exposure, and only slightly elevated odds of ADHD in relation to BDCIPP; Doherty et al. did not evaluate DnBP or BBOEP so comparisons could not be made for these OPEs. Differences between our study and Doherty et al. may be attributed to differences between time of exposure collection or differences in OPE levels between our study populations. For example, Doherty et al. collected urine samples later in pregnancy, specifically around 27 weeks' gestation, whereas urine samples in MoBa were collected at approximately 17 weeks' gestation. OPEs have low to moderate reliability when measured ~10 weeks' apart[85–92], therefore it could be that associations vary due to differences in an underlying susceptible window.[93] Furthermore, in general, exposure levels in our study were somewhat lower than Doherty et al., which would likely have impacted our precision and statistical power for tests of association.

Our results should also be interpreted in conjunction with those of Choi (2021) et al., who also used a nested substudy of MoBa but leveraged the NPR for registered ADHD diagnoses mostly in childhood (i.e. ages 6 to 11 years; 12 preschool ADHD cases in this study overlapped with NPR registered ADHD cases in the Choi et al. study).[12,53] Similar to ours, Choi et al. found a weak trend between higher BDCIPP exposure and greater ADHD risk, but no association with BBOEP.[12] Choi et al. also observed greater than medium DPhP exposure was associated with higher ADHD risk, although found no associations for DnBP exposure.[12] However, it is important to note that the cases included their study were ADHD registrations in the NPR. Because a gold standard for ADHD diagnosis does not exist, medical registry cases may be affected by provider-level differences in diagnostic procedures. Additionally, as children had to be referred to a specialist provider for evaluation, more severe or more disruptive ADHD cases are likely to be referred, whereas primarily inattentive cases, found more often among girls, may be under-represented. As such, the Choi et al. study had fewer ADHD cases among girls as compared to our study [Choi et al.: 28% ADHD cases were girls; our study: 44% ADHD cases were girls]. It is also important to note that while the demographic and behavioral risk factors commonly associated with ADHD in childhood (prenatal smoking, young maternal age, low maternal education, skewed toward male sex) were also found to be over-represented among our preschool ADHD cases, preschool ADHD symptoms do not always persist into childhood.[28,29] It has been suggested that the persistence of the preschool ADHD phenotype is ~90% over the course of childhood and adolescence.[28,29] Therefore, differences between our results and those of Choi et al. may be attributable to etiological differences between preschool ADHD and childhood ADHD.

Sexually dimorphic differences of the relationship between OPEs and ADHD have been observed in humans, with female-only dysregulation of thyroid hormones,[94,95] and through androgen-based mechanisms [96–99]. The epidemiological findings on EMM of the OPE-ADHD relationship by child sex have been mixed with one study finding larger adverse effects in girls compared to boys[12] and two studies generally observing no associations[9,11]. However, all studies to date (including ours) have had low statistical power to assess EMM, which could result in the observed study differences. Although we found a statistically significant sex-related EMM for BBOEP in our study, odds of ADHD were lower with

higher exposure to BBOEP among girls, with the opposite pattern found among boys. This was consistent with the only other study on OPEs and ADHD[12] but inconsistent with two other OPE studies evaluating ADHD -related symptoms that observed no appreciable sex-specific effects[9,11]. As such, there is a lack of consensus overall as to the presence of sex-related heterogeneity.

Some study limitations should be noted. In our study, OPE exposure was measured using a single spot urine collection at 17 weeks' gestation. This is not ideal as OPEs have relatively short half-lives lasting only 1 to 5 days[100,101] and have been found to have low (DnBP[85], DPhP[85,87–92,102]) to moderate (BDCIPP[85,86,88–92,102]) reliability when assessed 2 to 3 months apart (no epidemiological studies on reliability were found for BBOEP). As such, the OPE metabolite measurements in our study may not reflect OPE exposure throughout pregnancy. Although the pregnancy period of susceptibility for OPEs and neurodevelopment is unknown, the second trimester is a particularly sensitive window for brain growth and development, where adverse exposures could be more salient in terms of long-term neurological effects.[103,104] However, DPhP is a non-specific metabolite of TPhP and can be produced by several other parent compounds including resorcinol bis(diphenyl phosphate) [105], ethylhexyldiphenyl phosphate[106], and tert-butylphenyl diphenyl phosphate[107]. Therefore, DPhP concentrations in our study may in part reflect exposure to another parent compound that could have a different toxicity compared to TPhP. However, DPhP is the field standard biomarker for TPhP, and most previous studies observed an association between gestational DPhP exposure and ADHD or ADHD-like symptoms[11,12]. Additionally, because OPE exposure occurs as a mixture rather than in isolation, the potential for co-pollutant confounding, synergistic and/or antagonistic interactions, and/or cumulative (i.e. joint) effects cannot be dismissed, although it is unlikely that our findings represent underestimation of real effects due to these phenomena.[108] In our study we found low correlations between our 4 measured OPEs, and, in a sensitivity analysis, mutual adjustment for other OPEs did not impact any of our estimates. Furthermore, although preschool ADHD is a valid measure[26], it has low continuity with childhood ADHD and is difficult to diagnose as many of the symptoms associated with preschool ADHD are considered normative for this age-group. [27,109] This study attempts to minimize the potential for misclassification of ADHD in the preschool period by only assessing these outcomes using a validated instrument specifically designed for preschoolers, PAPA, consisting of an in-person in-depth standardized interview conducted by trained personnel. As a result, these measures provide us greater confidence in their accuracy compared to the use of other methods such as diagnostic codes. Regardless, outcome misclassification for ADHD would not likely strongly impact effect estimates as the misclassification is not expected to be differential by exposure. Finally, there is the possibility that selection bias may affect our results given that only the cases were assessed via an in-person assessment whereas non-cases were not.[110]

Our study has several important strengths. This case-control study was nested within the large and well characterized Norwegian Mother, Father, and Child cohort (MoBa). Our preschool ADHD cases were identified using a high-quality and validated clinical assessment tool for the preschool period, the Preschool Aged Psychiatric Assessment. The clinical assessment was found to have high inter-rater reliability and was conducted under

the supervision of a child psychologist or psychiatrist.[111] As a result, this study is less likely to suffer from outcome misclassification compared to studies relying on self-report.[109] This study also utilized biomarkers of OPEs rather than reliance on external measures such as household dust. Biomarkers inherently integrate exposure from all sources, thus accounting for the diverse potential sources of OPE exposure including cars[112,113], residential housing [16,113–116], and office spaces [112,113,116], as well as potential exposure from food[117–119] and water[120–122]. Therefore, utilization of biomarkers in our study rather than external measures has the potential to contribute to greater exposure validity. Additionally, this study also has a good representation of girls (44%) allowing for greater statistical power to assess EMM of the OPE-ADHD relationship by child sex. Our study also fills an important research gap on the OPEs DnBP and BBOEP as TBOEP and TnBP are frequently reported as two of the highest OPE concentrations in dust (particularly in Europe) and have been found to be associated with developmental toxicity and dysregulation of thyroid hormones.[123–125]

Conclusions

OPEs are ubiquitous[1–5] and increasing in usage[1], although there is a paucity of research on their safety. Our results support a modest and imprecise association between DnBP and BDCIPP with preschool ADHD. Preschool ADHD is a prevalent neurodevelopmental disorder[126–128] with substantial adverse individual[129,130] and economic[36–41] consequences. As such, identification of potentially-modifiable risk factors for this common and impactful neurodevelopment disorder is critically needed.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements:

Abbreviations

ADHD	Attention-deficit/hyperactivity-disorder
BBOEP	Bis(2-butoxyethyl) phosphate
BDCIPP	Bis(1,3-dichloro-2-propyl) phosphate

DnBP	Di-n-butyl phosphate
DPhP	Diphenyl phosphate
EMM	Effect measure modification
LOD	Limit of detection
LOQ	Limit of quantification
MoBa	The Norwegian Mother, Father, and Child Cohort Study
OPE	Organophosphate ester
PAPA	Preschool Age Psychiatric Assessment
PBDEs	Polybrominated diphenyl esters
PCBs	Polychlorinated biphenyls
TBOEP	Tris (2-butoxethly) phosphate
TDCIPP	Tris (1,3-dichloro-2-propyl) phosphate
TnBP	Tri-n-butyl phosphate
TPhP	Triphenyl phosphate

References

1. van der Veen I, de Boer J. Phosphorus flame retardants: properties, production, environmental occurrence, toxicity and analysis. Chemosphere 2012;88(10):1119–53. [PubMed: 22537891]

2. Stapleton HM, Klosterhaus S, Keller A, et al. Identification of flame retardants in polyurethane foam collected from baby products. Environmental science & technology 2011;45(12):5323–5331. [PubMed: 21591615]

3. Ingle ME, Mínguez-Alarcón L, Carignan CC, et al. The association of urinary phosphorous-containing flame retardant metabolites and self-reported personal care and household product use among couples seeking fertility treatment. Journal of exposure science & environmental epidemiology 2020;30(1):107–116. [PubMed: 30728482]

4. Ingle ME, Watkins D, Rosario Z, et al. The association of urinary organophosphate ester metabolites and self-reported personal care and household product use among pregnant women in Puerto Rico. Environmental research 2019;179:108756. [PubMed: 31574449]

5. Mendelsohn E, Hagopian A, Hoffman K, et al. Nail polish as a source of exposure to triphenyl phosphate. Environment international 2016;86:45–51. [PubMed: 26485058]

6. Morelle R PCB chemical threat to Europe's killer whales and dolphins. BBC News 2016.

7. European Union (EU). Diphenyl ether, pentabromo derivative (pentabromodiphenyl ether). European Union Risk Assessment Report: Luxembourg: Office for Official Publications of the European Committees, 2001.

8. Lipscomb ST, McClelland MM, MacDonald M, et al. Cross-sectional study of social behaviors in preschool children and exposure to flame retardants. Environ Health 2017;16(1):23. [PubMed: 28274271]

9. Castorina R, Bradman A, Stapleton HM, et al. Current-use flame retardants: Maternal exposure and neurodevelopment in children of the CHAMACOS cohort. Chemosphere 2017;189:574–580. [PubMed: 28963974]

10. Doherty BT, Hoffman K, Keil AP, et al. Prenatal exposure to organophosphate esters and cognitive development in young children in the Pregnancy, Infection, and Nutrition Study. Environ Res 2018;169:33–40. [PubMed: 30408751]

11. Doherty BT, Hoffman K, Keil AP, et al. Prenatal exposure to organophosphate esters and behavioral development in young children in the Pregnancy, Infection, and Nutrition Study. Neurotoxicology 2019;73:150–160. [PubMed: 30951742]

12. Choi G, Keil AP, Richardson DB, et al. Pregnancy exposure to organophosphate esters and the risk of attention-deficit hyperactivity disorder in the Norwegian mother, father and child cohort study. Environment international 2021;154:106549. [PubMed: 33910116]

13. Hoffman K, Lorenzo A, Butt CM, et al. Exposure to flame retardant chemicals and occurrence and severity of papillary thyroid cancer: A case-control study. Environment international 2017;107:235–242. [PubMed: 28772138]

14. Preston EV, McClean MD, Henn BC, et al. Associations between urinary diphenyl phosphate and thyroid function. Environment international 2017;101:158–164. [PubMed: 28162782]

15. Carignan CC, Mínguez-Alarcón L, Williams PL, et al. Paternal urinary concentrations of organophosphate flame retardant metabolites, fertility measures, and pregnancy outcomes among couples undergoing in vitro fertilization. Environment international 2018;111:232–238. [PubMed: 29241080]

16. Meeker JD, Cooper EM, Stapleton HM, Hauser R. Urinary metabolites of organophosphate flame retardants: temporal variability and correlations with house dust concentrations. Environmental health perspectives 2013;121(5):580–585. [PubMed: 23461877]

17. Meeker JD, Johnson PI, Camann D, Hauser R. Polybrominated diphenyl ether (PBDE) concentrations in house dust are related to hormone levels in men. Science of the Total Environment 2009;407(10):3425–3429. [PubMed: 19211133]

18. Bamai YA, Araki A, Nomura T, et al. Association of filaggrin gene mutations and childhood eczema and wheeze with phthalates and phosphorus flame retardants in house dust: The Hokkaido study on Environment and Children's Health. Environment international 2018;121:102–110. [PubMed: 30195067]

19. Araki A, Bastiaensen M, Bamai YA, et al. Associations between allergic symptoms and phosphate flame retardants in dust and their urinary metabolites among school children. Environment international 2018;119:438–446. [PubMed: 30031263]

20. Araki A, Saito I, Kanazawa A, et al. Phosphorus flame retardants in indoor dust and their relation to asthma and allergies of inhabitants. Indoor air 2014;24(1):3–15. [PubMed: 23724807]

21. Deziel NC, Yi H, Stapleton HM, et al. A case-control study of exposure to organophosphate flame retardants and risk of thyroid cancer in women. BMC cancer 2018;18(1):1–10. [PubMed: 29291726]

22. Canbaz D, Van Velzen M, Hallner E, et al. Exposure to organophosphate and polybrominated diphenyl ether flame retardants via indoor dust and childhood asthma. Indoor Air 2016;26(3):403–413. [PubMed: 25952720]

23. Ding J, Xu Z, Huang W, Feng L, Yang F. Organophosphate ester flame retardants and plasticizers in human placenta in Eastern China. Sci Total Environ 2016;554–555:211–7. [PubMed: 27552133]

24. Wang Q, Liang K, Liu J, et al. Exposure of zebrafish embryos/larvae to TDCPP alters concentrations of thyroid hormones and transcriptions of genes involved in the hypothalamic–pituitary–thyroid axis. Aquatic toxicology 2013;126:207–213. [PubMed: 23220413]

25. Bai XY, Lu SY, Xie L, et al. A pilot study of metabolites of organophosphorus flame retardants in paired maternal urine and amniotic fluid samples: potential exposure risks of tributyl phosphate to pregnant women. Environ Sci Process Impacts 2019;21(1):124–132. [PubMed: 30427354]

26. Pediatrics AAo. AAP Expands Ages for Diagnosis and Treatment of ADHD in Children https://www.aap.org/en-us/about-the-aap/aap-press-room/pages/AAP-Expands-Ages-for-Diagnosis-and-Treatment-of-ADHD-in-Children.aspx Accessed January 31,2019.

27. Overgaard KR, Oerbeck B, Friis S, et al. Attention-deficit/hyperactivity disorder from preschool to school age: change and stability of parent and teacher reports. European Child & Adolescent Psychiatry 2022:1–9.

28. Riddle MA, Yershova K, Lazzaretto D, et al. The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) 6-year follow-up. J Am Acad Child Adolesc Psychiatry 2013;52(3):264–278 e2. [PubMed: 23452683]

29. Lahey BB, Lee SS, Sibley MH, et al. Predictors of adolescent outcomes among 4–6-year-old children with attention-deficit/hyperactivity disorder. J Abnorm Psychol 2016;125(2):168–181. [PubMed: 26854503]

30. de Zeeuw EL, van Beijsterveldt CEM, Ehli EA, de Geus EJC, Boomsma DI. Attention Deficit Hyperactivity Disorder Symptoms and Low Educational Achievement: Evidence Supporting A Causal Hypothesis. Behav Genet 2017;47(3):278–289. [PubMed: 28191586]

31. Galera C, Melchior M, Chastang JF, Bouvard MP, Fombonne E. Childhood and adolescent hyperactivity-inattention symptoms and academic achievement 8 years later: the GAZEL Youth study. Psychol Med 2009;39(11):1895–906. [PubMed: 19335935]

32. Rokeach A, Wiener J. The Romantic Relationships of Adolescents With ADHD. J Atten Disord 2018;22(1):35–45. [PubMed: 24972794]

33. Sarkis E Addressing attention-deficit/hyperactivity disorder in the workplace. Postgrad Med 2014;126(5):25–30.

34. Quintero J, Morales I, Vera R, Zuluaga P, Fernandez A. The Impact of Adult ADHD in the Quality of Life Profile. J Atten Disord 2017:1087054717733046.

35. Lee YC, Yang HJ, Chen VC, et al. Meta-analysis of quality of life in children and adolescents with ADHD: By both parent proxy-report and child self-report using PedsQL. Res Dev Disabil 2016;51–52:160–72.

36. Sciberras E, Lucas N, Efron D, et al. Health Care Costs Associated With Parent-Reported ADHD: A Longitudinal Australian Population-Based Study. J Atten Disord 2017;21(13):1063–1072. [PubMed: 23816972]

37. Gupte-Singh K, Singh RR, Lawson KA. Economic Burden of Attention-Deficit/Hyperactivity Disorder among Pediatric Patients in the United States. Value Health 2017;20(4):602–609. [PubMed: 28408002]

38. Le HH, Hodgkins P, Postma MJ, et al. Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case. Eur Child Adolesc Psychiatry 2014;23(7):587–98. [PubMed: 24166532]

39. Quintero J, Ramos-Quiroga JA, Sebastian JS, et al. Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis. BMC Psychiatry 2018;18(1):40. [PubMed: 29422022]

40. Cadman T, Eklund H, Howley D, et al. Caregiver burden as people with autism spectrum disorder and attention-deficit/hyperactivity disorder transition into adolescence and adulthood in the United Kingdom. J Am Acad Child Adolesc Psychiatry 2012;51(9):879–88. [PubMed: 22917201]

41. Kotsopoulos N, Connolly MP, Sobanski E, Postma MJ. The fiscal consequences of ADHD in Germany: a quantitative analysis based on differences in educational attainment and lifetime earnings. J Ment Health Policy Econ 2013;16(1):27–33. [PubMed: 23676413]

42. Magnus P The Norwegian Mother and Child Cohort Study (MoBa)–new research possibilities. Norsk epidemiologi 2007;17(2).

43. Magnus P, Birke C, Vejrup K, et al. Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol 2016;45(2):382–8. [PubMed: 27063603]

44. Kamai EM, Villanger GD, Nethery RC, et al. Gestational phthalate exposure and preschool attention deficit hyperactivity disorder in Norway. Environmental Epidemiology 2021;5(4).

45. Stoltenberg C, Schjølberg S, Bresnahan M, et al. The Autism Birth Cohort: a paradigm for gene–environment–timing research. Molecular psychiatry 2010;15(7):676–680. [PubMed: 20571529]

46. Engel SM, Villanger GD, Nethery RC, et al. Prenatal Phthalates, Maternal Thyroid Function, and Risk of Attention-Deficit Hyperactivity Disorder in the Norwegian Mother and Child Cohort. Environ Health Perspect 2018;126(5):057004. [PubMed: 29790729]

47. Overgaard KR, Oerbeck B, Friis S, et al. Predictive validity of attention-deficit/hyperactivity disorder from ages 3 to 5 Years. European Child & Adolescent Psychiatry 2022;31(7):1–10.

48. Biele G, Overgaard KR, Friis S, Zeiner P, Aase H. Cognitive, emotional, and social functioning of preschoolers with attention deficit hyperactivity problems. BMC psychiatry 2022;22(1):1–10. [PubMed: 34983462]

49. Association AP. Diagnostic and statistical manual of mental disorders: DSM-IV-TR Washington, DC: American Psychiatric Association 2000.

50. Achenbach TM, Rescorla LA. Multicultural supplement to the manual for the ASEBA preschool forms & profiles: child behavior checklist for ages 1 1/2–5, language development survey, caregiver-teacher report form; an integrated system of multi-informant assessment University of Vermont, research center for children youth & families, 2010.

51. Ahmad SA, Warriner EM. Review of the NEPSY: a developmental neuropsychological assessment. Clin Neuropsychol 2001;15(2):240–9. [PubMed: 11530782]

52. Skogan AH, Zeiner P, Egeland J, et al. Parent ratings of executive function in young preschool children with symptoms of attention-deficit/-hyperactivity disorder. Behavioral and Brain Functions 2015;11(1):1–11. [PubMed: 25595193]

53. Surén P, Bakken IJ, Aase H, et al. Autism spectrum disorder, ADHD, epilepsy, and cerebral palsy in Norwegian children. Pediatrics 2012;130(1):e152–e158. [PubMed: 22711729]

54. Lahey BB, Pelham WE, Loney J, Lee SS, Willcutt E. Instability of the DSM-IV Subtypes of ADHD from preschool through elementary school. Arch Gen Psychiatry 2005;62(8):896–902. [PubMed: 16061767]

55. Leopold DR, Christopher ME, Burns GL, et al. Attention-deficit/hyperactivity disorder and sluggish cognitive tempo throughout childhood: temporal invariance and stability from preschool through ninth grade. J Child Psychol Psychiatry 2016;57(9):1066–74. [PubMed: 26749438]

56. Curchack-Lichtin JT, Chacko A, Halperin JM. Changes in ADHD symptom endorsement: preschool to school age. J Abnorm Child Psychol 2014;42(6):993–1004. [PubMed: 24343794]

57. Egger HL, & Angold A The Preschool Age Psychiatric Assessment (PAPA): A structured parent interview for diagnosing psychiatric disorders in preschool children.. Handbook of infant, toddler, and preschool mental health assessment 2004;42(5):223–243.

58. Egger HL, Erkanli A, Keeler G, et al. Test-Retest Reliability of the Preschool Age Psychiatric Assessment (PAPA). J Am Acad Child Adolesc Psychiatry 2006;45(5):538–49. [PubMed: 16601400]

59. Rohrer-Baumgartner N, Zeiner P, Egeland J, et al. Does IQ influence Associations between ADHD Symptoms and other Cognitive Functions in young Preschoolers? Behavioral and Brain Functions 2014;10(1):1–11. [PubMed: 24405777]

60. Øvergaard KR, Oerbeck B, Friis S, et al. Attention-deficit/hyperactivity disorder in preschoolers: the accuracy of a short screener. Journal of the American Academy of Child & Adolescent Psychiatry 2018;57(6):428–435. [PubMed: 29859558]

61. Bendiksen B, Svensson E, Aase H, et al. Co-occurrence of ODD and CD in preschool children with symptoms of ADHD. Journal of attention disorders 2017;21(9):741–752. [PubMed: 24994876]

62. Rønningen KS, Paltiel L, Meltzer HM, et al. The biobank of the Norwegian Mother and Child Cohort Study: a resource for the next 100 years. European journal of epidemiology 2006;21(8):619–625. [PubMed: 17031521]

63. Paltiel L, Anita H, Skjerden T, et al. The biobank of the Norwegian Mother and Child Study–present status. Norsk epidemiologi 2014;24(1–2).

64. Hoppin JA, Ulmer R, Calafat AM, et al. Impact of urine preservation methods and duration of storage on measured levels of environmental contaminants. J Expo Sci Environ Epidemiol 2006;16(1):39–48. [PubMed: 16007114]

65. Cequier E, Marcé RM, Becher G, Thomsen C. A high-throughput method for determination of metabolites of organophosphate flame retardants in urine by ultra performance liquid chromatography–high resolution mass spectrometry. Analytica chimica acta 2014;845:98–104. [PubMed: 25201278]

66. Choi G, Keil AP, Villanger GD, et al. Pregnancy exposure to common-detect organophosphate esters and phthalates and maternal thyroid function. Science of The Total Environment 2021;782:146709. [PubMed: 33839654]

67. Engel SM, Villanger GD, Nethery RC, et al. Prenatal phthalates, maternal thyroid function, and risk of attention-deficit hyperactivity disorder in the Norwegian mother and child cohort. Environmental health perspectives 2018;126(5):057004. [PubMed: 29790729]

68. Pearl J, Robins JM. Probabilistic evaluation of sequential plans from causal models with hidden variables. UAI: Citeseer, 1995;444–453.

69. Sala B, Giménez J, Fernández-Arribas J, et al. Organophosphate ester plasticizers in edible fish from the Mediterranean Sea: marine pollution and human exposure. Environmental Pollution 2022;292:118377. [PubMed: 34656682]

70. Choi Y, Hao C, Helm PA, Bhavsar SP, Kim SD. Organophosphate esters in Great Lakes fish: An improved analysis to assess concentrations and human exposure via consumption. Science of The Total Environment 2022;807:150981. [PubMed: 34666087]

71. Brantsæter AL, Haugen M, Alexander J, Meltzer HM. Validity of a new food frequency questionnaire for pregnant women in the Norwegian Mother and Child Cohort Study (MoBa). Maternal & child nutrition 2008;4(1):28–43. [PubMed: 18171405]

72. Kessler RC, Adler L, Ames M, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychological medicine 2005;35(2):245. [PubMed: 15841682]

73. Banerjee TD, Middleton F, Faraone SV. Environmental risk factors for attention-deficit hyperactivity disorder. Acta paediatrica 2007;96(9):1269–1274. [PubMed: 17718779]

74. Silberg JL, Gillespie N, Moore AA, et al. Shared genetic and environmental influences on early temperament and preschool psychiatric disorders in Hispanic twins. Twin Res Hum Genet 2015;18(2):171–8. [PubMed: 25728588]

75. Freitag CM, Rohde LA, Lempp T, Romanos M. Phenotypic and measurement influences on heritability estimates in childhood ADHD. Eur Child Adolesc Psychiatry 2010;19(3):311–23. [PubMed: 20213230]

76. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57(11):1313–23. [PubMed: 15950004]

77. Lubin JH, Colt JS, Camann D, et al. Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect 2004;112(17):1691–6. [PubMed: 15579415]

78. Hauser R, Meeker JD, Park S, Silva MJ, Calafat AM. Temporal variability of urinary phthalate metabolite levels in men of reproductive age. Environmental health perspectives 2004;112(17):1734–1740. [PubMed: 15579421]

79. Rubin DB. Multiple imputation for survey nonresponse New York: Wiley, 1987.

80. Harel O, Mitchell EM, Perkins NJ, et al. Multiple Imputation for Incomplete Data in Epidemiologic Studies. Am J Epidemiol 2018;187(3):576–584. [PubMed: 29165547]

81. Allison PD. Missing data Vol. 136 Sage publications, 2001.

82. Buckley JP, Doherty BT, Keil AP, Engel SM. Statistical approaches for estimating sex-specific effects in endocrine disruptors research. Environmental health perspectives 2017;125(6):067013. [PubMed: 28665274]

83. Dishaw LV, Powers CM, Ryde IT, et al. Is the PentaBDE replacement, tris (1, 3-dichloro-2-propyl) phosphate (TDCPP), a developmental neurotoxicant? Studies in PC12 cells. Toxicology and applied pharmacology 2011;256(3):281–289. [PubMed: 21255595]

84. Gu Y, Yang Y, Wan B, Li M, Guo L-H. Inhibition of O-linked N-acetylglucosamine transferase activity in PC12 cells–A molecular mechanism of organophosphate flame retardants developmental neurotoxicity. Biochemical pharmacology 2018;152:21–33. [PubMed: 29559311]

85. Percy Z, Vuong AM, Ospina M, et al. Organophosphate esters in a cohort of pregnant women: Variability and predictors of exposure. Environ Res 2020;184:109255. [PubMed: 32087441]

86. Carignan CC, Minguez-Alarcon L, Williams PL, et al. Paternal urinary concentrations of organophosphate flame retardant metabolites, fertility measures, and pregnancy outcomes among couples undergoing in vitro fertilization. Environ Int 2018;111:232–238. [PubMed: 29241080]

87. Zhao F, Kang Q, Zhang X, Liu J, Hu J. Urinary biomarkers for assessment of human exposure to monomeric aryl phosphate flame retardants. Environ Int 2019;124:259–264. [PubMed: 30660026]

88. Kuiper JR, Stapleton HM, Wills-Karp M, et al. Predictors and reproducibility of urinary organophosphate ester metabolite concentrations during pregnancy and associations with birth outcomes in an urban population. Environ Health 2020;19(1):55. [PubMed: 32448197]

89. Ingle ME, Watkins D, Rosario Z, et al. The association of urinary organophosphate ester metabolites and self-reported personal care and household product use among pregnant women in Puerto Rico. Environ Res 2019;179(Pt A):108756. [PubMed: 31574449]

90. Ingle ME, Watkins D, Rosario Z, et al. An exploratory analysis of urinary organophosphate ester metabolites and oxidative stress among pregnant women in Puerto Rico. Sci Total Environ 2020;703:134798. [PubMed: 31726298]

91. Meeker JD, Cooper EM, Stapleton HM, Hauser R. Urinary metabolites of organophosphate flame retardants: temporal variability and correlations with house dust concentrations. Environ Health Perspect 2013;121(5):580–5. [PubMed: 23461877]

92. Romano ME, Hawley NL, Eliot M, et al. Variability and predictors of urinary concentrations of organophosphate flame retardant metabolites among pregnant women in Rhode Island. Environ Health 2017;16(1):40. [PubMed: 28399857]

93. de Graaf-Peters VB, Hadders-Algra M. Ontogeny of the human central nervous system: what is happening when? Early human development 2006;82(4):257–266. [PubMed: 16360292]

94. Xu T, Wang Q, Shi Q, et al. Bioconcentration, metabolism and alterations of thyroid hormones of Tris (1, 3-dichloro-2-propyl) phosphate (TDCPP) in Zebrafish. Environmental toxicology and pharmacology 2015;40(2):581–586. [PubMed: 26356387]

95. Liu X, Jung D, Jo A, et al. Long-term exposure to triphenylphosphate alters hormone balance and HPG, HPI, and HPT gene expression in zebrafish (Danio rerio). Environ Toxicol Chem 2016;35(9):2288–96. [PubMed: 26865342]

96. Kojima H, Takeuchi S, Van den Eede N, Covaci A. Effects of primary metabolites of organophosphate flame retardants on transcriptional activity via human nuclear receptors. Toxicology letters 2016;245:31–39. [PubMed: 26778350]

97. Kojima H, Takeuchi S, Itoh T, et al. In vitro endocrine disruption potential of organophosphate flame retardants via human nuclear receptors. Toxicology 2013;314(1):76–83. [PubMed: 24051214]

98. Ren X, Zhao X, Duan X, Fang Z. Enhanced bio-concentration of tris (1, 3-dichloro-2-propyl) phosphate in the presence of nano-TiO2 can lead to adverse reproductive outcomes in zebrafish. Environmental Pollution 2018;233:612–622. [PubMed: 29107901]

99. Reers AR, Eng ML, Williams TD, et al. The Flame-Retardant Tris (1, 3-dichloro-2-propyl) Phosphate Represses Androgen Signaling in Human Prostate Cancer Cell Lines. Journal of Biochemical and Molecular Toxicology 2016;30(5):249–257. [PubMed: 26709203]

100. Hou R, Xu Y, Wang Z. Review of OPFRs in animals and humans: Absorption, bioaccumulation, metabolism, and internal exposure research. Chemosphere 2016;153:78–90. [PubMed: 27010170]

101. Lynn RK, Wong K, Garvie-Gould C, Kennish JM. Disposition of the flame retardant, tris(1,3-dichloro-2-propyl) phosphate, in the rat. Drug Metab Dispos 1981;9(5):434–41. [PubMed: 6117442]

102. Hoffman K, Daniels JL, Stapleton HM. Urinary metabolites of organophosphate flame retardants and their variability in pregnant women. Environ Int 2014;63:169–72. [PubMed: 24316320]

103. Vohr BR, Davis EP, Wanke CA, Krebs NF. Neurodevelopment: the impact of nutrition and inflammation during preconception and pregnancy in low-resource settings. Pediatrics 2017;139(Supplement 1):S38–S49. [PubMed: 28562247]

104. Selevan SG, Kimmel CA, Mendola P. Identifying critical windows of exposure for children's health. Environmental health perspectives 2000;108(suppl 3):451–455. [PubMed: 10852844]

105. Ballesteros-Gomez A, Van den Eede N, Covaci A. In vitro human metabolism of the flame retardant resorcinol bis(diphenylphosphate) (RDP). Environ Sci Technol 2015;49(6):3897–904. [PubMed: 25692932]

106. Ballesteros-Gomez A, Erratico CA, Eede NV, et al. In vitro metabolism of 2-ethylhexyldiphenyl phosphate (EHDPHP) by human liver microsomes. Toxicol Lett 2015;232(1):203–12. [PubMed: 25448284]

107. Heitkamp MA, Freeman JP, McMillan DC, Cerniglia CE. Fungal metabolism of tert-butylphenyl diphenyl phosphate. Appl Environ Microbiol 1985;50(2):265–73. [PubMed: 4051482]

108. Braun JM. Early-life exposure to EDCs: role in childhood obesity and neurodevelopment. Nature Reviews Endocrinology 2017;13(3):161–173.

109. Frick PJ, Nigg JT. Current issues in the diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder. Annu Rev Clin Psychol 2012;8:77–107. [PubMed: 22035245]

110. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004:615–625. [PubMed: 15308962]

111. Overgaard KR, Oerbeck B, Friis S, et al. Attention-Deficit/Hyperactivity Disorder in Preschoolers: The Accuracy of a Short Screener. J Am Acad Child Adolesc Psychiatry 2018;57(6):428–435. [PubMed: 29859558]

112. Brommer S, Harrad S, Van den Eede N, Covaci A. Concentrations of organophosphate esters and brominated flame retardants in German indoor dust samples. J Environ Monit 2012;14(9):2482–7. [PubMed: 22854617]

113. Zhou L, Hiltscher M, Püttmann W. Occurrence and human exposure assessment of organophosphate flame retardants in indoor dust from various microenvironments of the Rhine/Main region, Germany. Indoor Air 2017;27(6):1113–1127. [PubMed: 28556503]

114. Ali N, Dirtu AC, Van den Eede N, et al. Occurrence of alternative flame retardants in indoor dust from New Zealand: indoor sources and human exposure assessment. Chemosphere 2012;88(11):1276–82. [PubMed: 22551874]

115. Cequier E, Ionas AC, Covaci A, et al. Occurrence of a broad range of legacy and emerging flame retardants in indoor environments in Norway. Environ Sci Technol 2014;48(12):6827–35. [PubMed: 24846325]

116. He R, Li Y, Xiang P, et al. Organophosphorus flame retardants and phthalate esters in indoor dust from different microenvironments: Bioaccessibility and risk assessment. Chemosphere 2016;150:528–535. [PubMed: 26585356]

117. Zhang X, Zou W, Mu L, et al. Rice ingestion is a major pathway for human exposure to organophosphate flame retardants (OPFRs) in China. Journal of hazardous materials 2016;318:686–693. [PubMed: 27484948]

118. Li J, Zhao L, Letcher RJ, et al. A review on organophosphate Ester (OPE) flame retardants and plasticizers in foodstuffs: Levels, distribution, human dietary exposure, and future directions. Environ Int 2019;127:35–51. [PubMed: 30901640]

119. Ding J, Deng T, Xu M, Wang S, Yang F. Residuals of organophosphate esters in foodstuffs and implication for human exposure. Environmental Pollution 2018;233:986–991. [PubMed: 29037495]

120. Li J, Yu N, Zhang B, et al. Occurrence of organophosphate flame retardants in drinking water from China. Water research 2014;54:53–61. [PubMed: 24556230]

121. Kim U-J, Occurrence Kannan K. and distribution of organophosphate flame retardants/plasticizers in surface waters, tap water, and rainwater: Implications for human exposure. Environmental science & technology 2018;52(10):5625–5633. [PubMed: 29659254]

122. Lee S, Jeong W, Kannan K, Moon H-B. Occurrence and exposure assessment of organophosphate flame retardants (OPFRs) through the consumption of drinking water in Korea. Water research 2016;103:182–188. [PubMed: 27450356]

123. Chupeau Z, Bonvallot N, Mercier F, et al. Organophosphorus Flame Retardants: A Global Review of Indoor Contamination and Human Exposure in Europe and Epidemiological Evidence. Int J Environ Res Public Health 2020;17(18).

124. Zhang Q, Ji C, Yin X, et al. Thyroid hormone-disrupting activity and ecological risk assessment of phosphorus-containing flame retardants by in vitro, in vivo and in silico approaches. Environ Pollut 2016;210:27–33. [PubMed: 26701863]

125. Liu Y, Wu D, Xu Q, et al. Acute exposure to tris (2-butoxyethyl) phosphate (TBOEP) affects growth and development of embryo-larval zebrafish. Aquat Toxicol 2017;191:17–24. [PubMed: 28772162]

126. Lavigne JV, Lebailly SA, Hopkins J, Gouze KR, Binns HJ. The prevalence of ADHD, ODD, depression, and anxiety in a community sample of 4-year-olds. J Clin Child Adolesc Psychol 2009;38(3):315–28. [PubMed: 19437293]

127. Wichstrom L, Berg-Nielsen TS, Angold A, et al. Prevalence of psychiatric disorders in preschoolers. J Child Psychol Psychiatry 2012;53(6):695–705. [PubMed: 22211517]

128. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 2012;9(3):490–9. [PubMed: 22976615]

129. Mariani MA, Barkley RA. Neuropsychological and academic functioning in preschool boys with attention deficit hyperactivity disorder. Developmental neuropsychology 1997;13(1):111–129.

130. GJ D McGoey KE Eckert TL VanBrakle J Preschool children with attention-deficit/hyperactivity disorder: Impairments in behavioral, social, and school functioning. J Am Acad Child Adolesc Psychiatry 2001;40:508–515. [PubMed: 11349694]

Highlights

- We evaluated the OPEs DnBP, DPhP, BBOEP, and BDCIPP and odds of preschool ADHD

- DnBP and BDCIPP were associated with increased odds of preschool ADHD

- Girls had lower odds of ADHD with increasing BBOEP and boys had increased odds

- DPhP was not associated with odds of preschool ADHD

Figure 1.
Associations between quartiles of DPhP and DnBP and categorized measures of BBOEP and BDCIPP, based on their limits of detection and quantification respectively, in relation to preschool ADHD in a nested case-control study of preschool ADHD in MoBa, 2004–2007 (N=809). All models are from an imputed logistic regression model adjusted for total fish consumption, maternal education, financial difficulty, and maternal age.

Table 1.

Characteristics of a nested case-control study of preschool ADHD in MoBa, 2004–2007.

	Preschool ADHD group	Controls[a]
	Mean (SD) or N (%)	*Mean (SD) or N (%)*
Total N	**260**	**549**
Maternal age at delivery (years)	*30.0 (4.05)*	*30.9 (4.23)*
Missing	0 (0.0)	2 (0.4)
Child sex, N		
Male	145 (55.8)	275 (50.1)
Female	115 (44.2)	274 (49.9)
Missing	0 (0.0)	0 (0.0)
Maternal education, N (%)		
Not a college graduate	92 (35.4)	121 (22.0)
College graduate	108 (41.5)	237 (43.2)
Post-college education	56 (21.5)	168 (30.6)
Missing	4 (1.5)	23 (4.2)
Marital status		
Single/Co-inhabiting	146 (56.2)	257 (46.8)
Married	113 (43.5)	287 (52.3)
Missing	1 (0.4)	5 (0.9)
Parity		
Nulliparous	156 (60.0)	270 (49.2)
Parous	104 (40.0)	277 (50.5)
Missing	0 (0.0)	2 (0.4)
Maternal ADHD symptoms	33 (12.7)	21 (3.8)
Missing	2 (0.8)	12 (2.2)
Maternal fish intake (g/day)	*26.2 (18.33)*	*27.4 (19.05)*
Missing	4 (1.5)	7 (1.3)
Any smoking in 1st or 2nd trimester	62 (23.8)	76 (13.8)
Missing	1 (0.4)	6 (1.1)
Any alcohol consumption in	32 (12.3)	65 (11.8)
1st or 2nd trimester		
Missing	21 (8.1)	44 (8.0)
Experienced financial difficulty in the past year[b]	67 (25.8)	75 (13.7)
Missing	1 (0.4)	2 (0.4)
Birth year		
2004	26 (10.0)	55 (10.0)
2005	62 (23.9)	131 (23.9)
2006	90 (34.6)	190 (34.6)
2007	82 (31.5)	173 (31.5)
Missing	0 (0.0)	0 (0.0)

^aControls are birth-year-stratified to account for changes in exposure or outcome frequency attributable to birth year.

^bPast year refers to the year before enrollment (around 17 weeks' gestation).

Table 2.

Gestational specific gravity-corrected OPE metabolite distribution in a nested case-control study of preschool ADHD in MoBa, 2004–2007.

Exposure	Geometric Mean[a]	Geometric SD[a]	Min	25%	50%	75%	Max	LOD[b]	% LOD[b]	LOQ[c]	%[c]
DPhP (ng/mL)								0.03		0.10	
Preschool ADHD (N=260)	0.48	2.95	<LOD	0.29	0.49	0.93	37.22		96.5%		92.3%
Controls[d] (N=549)	0.46	2.93	<LOD	0.26	0.48	0.88	11.16		96.5%		93.4%
DnBP (ng/mL)								0.07		0.20	
Preschool ADHD (N=260)	0.26	2.18	<LOD	0.17	0.25	0.37	10.93		95.4%		66.5%
Controls[d] (N=549)	0.25	2.36	<LOD	0.15	0.23	0.38	25.59		92.7%		58.5%
BBOEP (ng/mL)	-	-						0.07		0.20	
Preschool ADHD (N=260)	0.08	2.01	<LOD	<LOD	<LOD	0.13	0.84		44.2%		12.3%
Controls[d] (N=549)	0.09	2.13	<LOD	<LOD	<LOD	0.13	3.40		43.7%		14.6%
BDCIPP (ng/mL)								0.17		0.50	
Preschool ADHD (N=260)	0.17	2.40	<LOD	<LOD	<LOD	<LOD	16.83		20.4%		10.8%
Controls[d] (N=549)	0.18	2.72	<LOD	<LOD	<LOD	<LOD	96.92		19.5%		12.2%

[a] Values below the limit of detection (LOD) were imputed using for the geometric mean and standard deviation.

[b] Limit of detection.

[c] Limit of quantification.

[d] Controls are birth-year-stratified to account for changes in exposure or outcome frequency attributable to birth year.

Table 3.

Assessment of multiplicative effect measure modification by child sex for the relationship between gestational OPEs and preschool ADHD in a nested case-control study of preschool ADHD in MoBa, 2004–2007.

Exposure	Combined[a,b,c]	Boys[d,e]	Girls[d,f]	P-value[g]
	Odds Ratio (95% CI)	Odds Ratio (95% CI)	Odds	Odds Ratio (95% CI)
Log10 exposure				
DPhP	1.07 (0.77, 1.48)	0.95 (0.61, 1.49)	1.23 (0.76, 2.00)	0.45
DnBP	1.30 (0.86, 1.97)	1.47 (0.84, 2.57)	1.12 (0.60, 2.11)	0.54
Exposure LOD[g]				
BBOEP	0.94 (0.69, 1.28)	1.31 (0.86, 2.00)	0.58 (0.37, 0.93)	0.01
BDCIPP	1.19 (0.83, 1.71)	1.25 (0.74, 2.11)	1.07 (0.63, 1.80)	0.67

[a] Refers to full model without the incorporation of interaction terms.

[b] Combined model contains 260 Preschool ADHD cases and 549 birth-year-stratified controls.

[c] All models are derived from an imputed logistic regression model adjusted for total fish consumption, maternal education, financial difficulty, maternal age, and sex.

[d] Stratum-specific estimates are derived from models that additionally include interaction terms for each included variable using an augmented product term approach to assess effect measure modification by sex.

[e] Model for boys contains 145 Preschool ADHD cases and 275 birth-year-stratified controls.

[f] Model for girls contains 115 Preschool ADHD cases and 274 birth-year-stratified controls.

[g] P-value is derived from organophosphate ester*sex interaction.

[g] Limit of detection.